Breast cancer is the most frequently diagnosed cancer globally, annually affecting around 2 million women. Situation is getting worse with rising incidence linked to improved detection, risk factors, and enhanced registration systems. Conventional treatments like surgery, chemotherapy, radiotherapy, and hormonal therapy with several limitations are replaced by approaches like immunotherapy, HER2-targeted therapies, and nanotechnology offering improved outcomes, in metastatic cases. Risk factors range from lifestyle (alcohol, obesity, inactivity, smoking), to hormonal imbalance (early menarche, late menopause, nulliparity), to genetic aspects (BRCA1/2, TP53), to environmental determinants as well. Prognostic biomarkers now lead precision medicine: PR, ER, and HER2 stands strong as established pillars, while circulating tumor DNA, and immune-related markers such as PD-L1 offer profound perceptions into treatment response and disease progression. State-of-the-art treatment integrates traditional modalities like surgery, radiotherapy, and chemotherapy with targeted and immune-based therapies. Endocrine agents, PARP inhibitors, HER2-directed monoclonal antibodies, and checkpoint inhibitors exemplify the architype swing toward personalized, mechanism-based interventions. The insight underscores the need for twin tactics, leveraging molecular detections for precision oncology while guaranteeing impartial global access to modern therapies. Future progress depends on translational research, and biomarker validation that bridge the gap between innovation and accessibility.
Sengupta et al. (Fri,) studied this question.